Saisheng Pharmaceutical: Announcement on changes to subsidiary drug production licenses
Securities code: 300485 Securities abbreviation: Saisheng Pharmaceutical Announcement number: 2025-050
Beijing Saisheng Pharmaceutical Co., Ltd.
Announcement on changes to subsidiary drug production licenses
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and there are no false records, misleading statements or major omissions.
Shenyang Junyuan Pharmaceutical Co., Ltd. (hereinafter referred to as "Junyuan Pharmaceutical"), a subsidiary of Beijing Saisheng Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), recently obtained the "Drug Production License" issued by the Liaoning Provincial Food and Drug Administration. The matters involved in the changes this time are: it is agreed that the person in charge of production of the company will be changed from Li Li to Liu Huifeng, and other contents will remain unchanged. The relevant information is now announced as follows:
1. Basic information of "Drug Production License"
Company name: Shenyang Junyuan Pharmaceutical Co., Ltd.
License number: Liao20210198
Social credit code: 91210112MA0P430D6R
Category code: AhzBh
Registered address: Building 9, Shenyang Hunnan Biomedical Industrial Park, No. 603 Maizitun, Hunnan District, Shenyang City Legal representative: Wang Xuefeng
Person in charge of the company: Wang Guang
Production person in charge: Liu Huifeng
Quality manager: Tian Yuelin
Valid until: April 7, 2026
Production address and production scope:
Building 9, Building 22, No. 603 Maizitun, Hunnan District, Shenyang City: Tablets, granules, hard capsules, pills (water pills), solutions (external use, hormone-containing), tinctures (external use, hormone-containing), liniments, suppositories, small-volume injections***
2. Impact on the company
This "Pharmaceutical Production License" involves the change of the person in charge of production of the enterprise, which will help Junyuan Pharmaceutical continue to maintain stable production capacity, ensure the normal production and operation of Junyuan Pharmaceutical, and will not have a significant impact on the company's performance. Investors are kindly requested to invest rationally and pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Beijing Saisheng Pharmaceutical Co., Ltd.
November 25, 2025